Ad–αGal immunocomplexation following <i>i</i>.<i>m</i>. or <i>i</i>.<i>p</i>. immunization of anti-Gal mice significantly decreased Ad vector-directed CD8 T cell frequencies. by Ramona F. Kratzer (4002830)

Associations between the seven T2D risk variants and quantitative traits in up to 5,744 Danish individuals naive to glucose-lowering medication. by Marie Neergaard Harder (232759)

Nucleosome Repositioning: A Novel Mechanism for Nicotine- and Cocaine-Induced Epigenetic Changes by Amber N. Brown (800856)

“…Half of the drug-induced nucleosome positions approximated a theoretical model of nucleosome occupancy based on physical and chemical characteristics of the DNA sequence, whereas the basal or drug naïve positions were generally DNA sequence independent. …”

Circular Dichroism spectra for WT and three rhGH variants, observed at temperatures from 20 to 92C. by Andrei Rajkovic (10965915)

Gibberellic acid in <i>Citrus</i> spp. flowering and fruiting: A systematic review by Alfonso Garmendia (814091)

“…</p><p>Methods</p><p>An extensive literature search to obtain a large number of records about the topic was done. …”

Population characteristics. by O. Stivalet (6890189)

Flow chart. by O. Stivalet (6890189)

Forest plot for subgroup analyses by region. by Beshada Zerfu Woldegeorgis (12916598)

“…<div><p>Neonatal birth trauma, although it has steadily decreased in industrialized nations, constitutes a significant health burden in low-resource settings. …”

Regression graph of neonatal birth trauma. by Beshada Zerfu Woldegeorgis (12916598)

“…<div><p>Neonatal birth trauma, although it has steadily decreased in industrialized nations, constitutes a significant health burden in low-resource settings. …”

Pattern and trend of neonatal birth trauma. by Beshada Zerfu Woldegeorgis (12916598)

“…<div><p>Neonatal birth trauma, although it has steadily decreased in industrialized nations, constitutes a significant health burden in low-resource settings. …”

Data extraction sheet. by Beshada Zerfu Woldegeorgis (12916598)

“…<div><p>Neonatal birth trauma, although it has steadily decreased in industrialized nations, constitutes a significant health burden in low-resource settings. …”

Funnel plot for publication bias. by Beshada Zerfu Woldegeorgis (12916598)

“…<div><p>Neonatal birth trauma, although it has steadily decreased in industrialized nations, constitutes a significant health burden in low-resource settings. …”

Depletion of SAMHD1 induces R-loop-mediated genome instability and cellular DNA damage response. by Kiwon Park (6492266)

Cell viability estimated with methylene blue dye. by Suélen Fernandes Silva (9510620)

“…<p>ScDHS and DHS-complemented yeast strains after incubation with 1 mM GC7 or with the vehicle (0 mM GC7) were labeled with methylene blue for 5 min at room temperature. ScDHS was also treated with 10 mM H₂O₂ as a positive control of decrease of yeast cell viability (control). …”

Fig 4 - by Hyuk Sung Yoon (20208672)

Decreased ecdysone signalling in the midgut results in significant decrease in mRNA levels for: <i>cecropin A1</i> (<i>lsmeans(pairwise~Genotype|P0)<0</i>.<i>0001; lsmeans(pairwise... by Catarina Nunes (3542330)

Depletion of SAMHD1 induces cell cycle delay and spontaneous DNA damage response. by Kiwon Park (6492266)

DataSheet2_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

“…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”

DataSheet3_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

“…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”

DataSheet1_First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.docx by Qiao Liu (346535)

“…</p><p>Conclusion: For advanced NSCLC patients with PD-L1 of at least 50%, cemiplimab was a cost-effective option compared with pembrolizumab and a dominant alternative against atezolizumab. …”